Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

989
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
989
Dementia01:30

Dementia

584
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
584
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

286
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
286
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

35
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phage intervention improves colitis and response to corticosteroids by attenuating virulence of Crohn's disease-associated bacteria.

Science translational medicine·2026
Same author

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.

Gut·2026
Same author

β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn's Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort.

Gastroenterology·2026
Same author

Interleukin23 Receptor Genetic Variants Associate With Crohn's Disease Risk and Microbiome Changes in Healthy First-Degree Relatives.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Fecal Microbiota Transplantation for Symptom Improvement in Patients With Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gastroenterology·2026

Related Experiment Video

Updated: Feb 17, 2026

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

75.8K

Proton Pump Inhibitors and Dementia: Deciphering the Data.

Paul Moayyedi1, Maxine A Lewis2

  • 1Farncombe Family Digestive Health Research Institute, Gastroenterology Division, McMaster University, Hamilton, Ontario, Canada.

The American Journal of Gastroenterology
|December 8, 2017
PubMed
Summary

Proton pump inhibitors (PPIs) do not increase the risk of Alzheimer's dementia, even with long-term use or higher doses. This study found no causal link between PPI medication and dementia development.

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K

Related Experiment Videos

Last Updated: Feb 17, 2026

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

75.8K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K

Area of Science:

  • Gastroenterology
  • Neurology
  • Pharmacology

Background:

  • Proton pump inhibitors (PPIs) effectively manage acid-related gastrointestinal disorders.
  • Long-term safety concerns for PPIs include potential risks of pneumonia, fractures, Clostridium difficile infection, chronic renal failure, and dementia.
  • Previous studies have suggested a possible association between PPI use and dementia, necessitating further investigation.

Purpose of the Study:

  • To investigate the association between proton pump inhibitor (PPI) use and the risk of developing Alzheimer's dementia.
  • To evaluate whether long-term PPI use or higher PPI doses are associated with an increased risk of dementia.

Main Methods:

  • Utilized healthcare registry data to analyze the relationship between PPI usage and Alzheimer's dementia incidence.
  • Conducted a retrospective cohort study to assess risks associated with PPIs.

Main Results:

  • The study found no statistically significant association between proton pump inhibitor use and the development of Alzheimer's dementia.
  • No increased risk of dementia was observed with prolonged PPI therapy or with higher dosages of PPIs.
  • Discrepancies with prior research may be attributed to issues like multiple testing and residual confounding.

Conclusions:

  • Current evidence does not support a causal relationship between proton pump inhibitor use and Alzheimer's dementia.
  • Further research is needed to definitively clarify the long-term safety profile of PPIs concerning neurological outcomes.